Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ

Clinical trial NCT05941481 · COMPLETED

Trial details

NCT number: NCT05941481
Sponsor: Jiangsu Cancer Institute & Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: 2023-06-10
Primary completion: 2025-03-15
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.